Edition:
United States

Biotechnology & Medical Research

Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

Nov 24 (Reuters) - Nektar Therapeutics :Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs.Nektar Therapeutics - costs related to concluding co’s activities related to Bayer's phase 3 Amikacin Inhale clinical program under 2007 agreement.Nektar...

6:21am EST

Klaria Pharma Q3 net loss narrows to SEK 1.2 million

Nov 24 (Reuters) - KLARIA PHARMA HOLDING AB (PUBL) :Q3 NET SALES SEK 2.3 MILLION VERSUS SEK 0 MILLION YEAR AGO​.Q3 LOSS AFTER TAX SEK 1.2 MILLION VERSUS LOSS SEK 3.2 MILLION YEAR AGO​.

2:30am EST

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.